The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness
Abstract
We here report a series of derivatives describing the structure-activity relationship around liraglutide, a once-daily human glucagon-like peptide-1 fatty acid derivative, with respect to potency as well as protraction in vivo. The spacer region between the fatty acid and the peptide is mostly important for potency, whereas the fatty acid or fatty acid mimetic is important for both potency and protraction. The length of the fatty acid is the most important parameter for protraction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LIR is suitable to be administered once a day, with a tmax of 9~13 hours and t1/2 of 13 hours (80–82).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [82]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAugeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Research works printed but not linked: 9
- Kim D., 2005, J. Med. Chem., 48, 151
- Vilsboll T., 2003, J. Clin. Endocrinol. Metab., 88, 224
- Edwards C. M. B., 2001, Am. J. Physiol. Endocrinol. Metab., 281, E161
- Kim J. G., 2003, Diabetes, 52, 759
- Dong J. Z., 2003, Biopolymers, 71, 2003
- Chou J. Z., 1997, J. Pharm. Sci., 86, 773
- Youn Y. S., 2007, Biochem. Pharmacol., 73, 93
- Degn K. B., 2004, Diabetes, 53, 1194
- DeFronzo R. A., 2005, Diabetes Care, 28, 1100
Cited by
Items 101–200 of 260
Trier, S., Linderoth, L., Bjerregaard, S., Strauss, H. M., Rahbek, U. L., & Andresen, T. L. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.09.001 · Cited by 28
van Witteloostuijn, S. B., Dalbøge, L. S., Hansen, G., Midtgaard, S. R., Jensen, G. V., Jensen, K. J., Vrang, N., Jelsing, J., & Pedersen, S. L. (2017) · Journal of Peptide Science · doi:10.1002/psc.3048 · Cited by 28
Zhang, L., Navaratna, T. A., & Thurber, G. M. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00209 · Cited by 28
The industrial design, translation, and development strategies for long-acting peptide delivery
Yang, B., dos Santos, A. G., Puri, S., Bak, A., & Zhou, L. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2098276 · Cited by 28
Nature-inspired and medicinally relevant short peptides
Ciulla, M. G., Civera, M., Sattin, S., & Kumar, K. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00011 · Cited by 28
Cross-Talk Between Insulin Signaling and G Protein–Coupled Receptors
Fu, Q., Shi, Q., West, T. M., & Xiang, Y. K. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000481 · Cited by 26
Novel therapeutic agents for the treatment of diabetic kidney disease
Hartman, R. E., Rao, S., Churchwell, M. D., & Lewis, S. J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1811231 · Cited by 26
Kim, J., Kim, J., Choi, C., Bae, J., & Choi, H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01497-y · Cited by 25
“Liraglutide, another early GLP-1R agonist, incorporates a fatty acid moiety that enhances albumin binding, extending its half-life 149,150 .”
Li, C.-G., Tang, W., Chi, X., Dong, Z.-M., Wang, X., & Wang, X. (2013) · Journal of Virology · doi:10.1128/jvi.01153-13 · Cited by 25
“The most typical derivatization involves long-chain fatty acids (10).”
BackgroundBenefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
Tanday, N., English, A. R., Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.674704 · Cited by 24
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Bak, M., Park, J., Min, K., Cho, J., Seong, J., Hahn, Y. S., Tae, G., & Kwon, I. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040364 · Cited by 24
“This K34R mutant has comparable biological activity to that of wild-type GLP-1 [48].”
BackgroundReplacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility
Lee, J. G., Ryu, J. H., Kim, S.-M., Park, M. Y., Kim, S.-H., Shin, Y. G., Sohn, J., Kim, H. H., Park, Z., Seong, J. Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.004 · Cited by 23
Half-Life Extending Modifications of Peptide YY3–36 Direct Receptor-Mediated Internalization
Bech, E. M., Kaiser, A., Bellmann‐Sickert, K., Bohr, S. S.-R., Sørensen, K. K., Elster, L., Hatzakis, N. S., Pedersen, S. L., Beck‐Sickinger, A. G., & Jensen, K. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00554 · Cited by 23
Sun, L., Huang, X., Han, J. D. J., Cai, X., Dai, Y., Chu, Y., Wang, C., Huang, W., & Qian, H. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.04.016 · Cited by 23
Small lipidated anti-obesity compounds derived from neuromedin U
Micewicz, E. D., Bahattab, O. S., Willars, G. B., Waring, A. J., Navab, M., Whitelegge, J. P., McBride, W. H., & Ruchala, P. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.020 · Cited by 22
Long-term delivery of protein and peptide therapeutics for cancer therapies
Sikder, S., Gote, V., Alshamrani, M., Sicotte, J., & Pal, D. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1662785 · Cited by 21
NESTOR, J. J. J., Zhang, X., Jaw‐Tsai, S., Parkes, D. G., & Becker, C. (2021) · Peptide Science · doi:10.1002/pep2.24221 · Cited by 21
Hasib, A., Ng, M. T., Tanday, N., Craig, S. L., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3106 · Cited by 21
“Indeed, this is exemplified by liraglutide, the clinically approved T2DM drug that has a C‐16 fatty acid molecule attached to Lys(26), enabling noncovalent self‐association with albumin.(20,21) For liraglutide, acylation does result in slightly lower intrinsic in vivo bioactivity,(22) but this is more than compensated…”
BackgroundAzad, B. B., Rota, V., Breadner, D. A., Dhanvantari, S., & Luyt, L. G. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.032 · Cited by 21
Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide
Guryanov, I., Bondesan, A., Visentini, D., Orlandin, A., Biondi, B., Toniolo, C., Formaggio, F., Ricci, A., Zanon, J., & Cabri, W. (2016) · Journal of Peptide Science · doi:10.1002/psc.2890 · Cited by 21
Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP-1
Welscher, Y. M. T., Chinnapen, D. J. ‐., Kaoutzani, L., Mrsny, R. J., & Lencer, W. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.12.013 · Cited by 20
Han, J. D. J., Fei, Y., Zhou, F. L., Chen, X., Zheng, W., & Fu, J. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00632 · Cited by 19
Artificial lipidation of proteins and peptides: from mechanism to clinical applications
Mu, J., Vong, E., & Carmali, S. (2025) · FEBS Journal · doi:10.1111/febs.70298 · Cited by 18
“The development of insulin detemir (Levemir (cid:2) ) established the foundation for next-generation glucagon-like peptide 1 (GLP-1) receptor agonists with fatty acid chain length serving as a key design parameter for controlling circulation time and dosing frequency [20].”
InfluentialChen, H., Lu, Y., Shi, S., Zhang, Q., Cao, X., Sun, L., An, D., Zhang, X., Kong, X., & Liu, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03265-3 · Cited by 18
“Meanwhile, semaglutide introduces a longer stearic (C18) di-acid fatty chain which is attached to Lys26 through one glutamic acid and two 8-amino-3,6- dioxaoctanoic acid (ADO) moieties (16).”
BackgroundDesign of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
Jiang, N., Jing, L., Li, Q., Su, S.-B., Yang, Q., Zhou, F. L., Chen, X., Han, J. D. J., Tang, C., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113118 · Cited by 18
Han, J. D. J., Zhou, F. L., Fei, Y., Chen, X., Fu, J., & Qian, H. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00712 · Cited by 18
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17
Sun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P. (2022) · Pharmaceuticals · doi:10.3390/ph15060740 · Cited by 17
“However, the high price of chemical modification also hinders the widespread use of such drugs(Elbrond et al. 2002; Madsen et al. 2007; Lau et al. 2015).”
BackgroundEmerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 18
“Duration of action 2 to 5 h [48, 51, 52] 12 h to up to a week [16, 53, 54]”
BackgroundBai, X., Niu, Y., Zhu, J., Yang, A.-Q., Wu, Y., & Ye, X. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.036 · Cited by 17
Amatya, R., Park, T., Hwang, S., Yang, J. W., Lee, Y.-J., Cheong, H., Moon, C., Kwak, H. D., Min, K. A., & Shin, M. C. (2020) · Toxins · doi:10.3390/toxins12050313 · Cited by 17
“Supporting this hypothesis, in related studies, increasing the cationicity or hydrophobicity of the peptides by appropriate amino acid substitution could have improved the potency, stimulating insulin release-possibly by promoting their membrane binding and internalization [55,56].”
MethodA Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands
Sicinski, K. M., Montanari, V., Raman, V. S., Doyle, J. R., Harwood, B. N., Song, Y. C., Fagan, M. P., Rios, M., Haines, D. R., Kopin, A. S., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01237 · Cited by 17
Han, J. D. J., Chen, X., Zhao, L., Fu, J., Sun, L., Zhang, Y., Zhou, F. L., & Fei, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00336 · Cited by 16
Ichikawa, M., Hirayama, T., Fukushima, M., Kitazawa, I., Kojima, K., Sakai, T., Takatsu, Y., & Ohtaki, T. (2018) · ACS Omega · doi:10.1021/acsomega.8b00467 · Cited by 16
Neuroprotective role of (Val 8 ) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
Liu, Y., Li, L., Liu, K., Zhao, J., Hölscher, C., & Li, G. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177742 · Cited by 15
“Based on the structural properties of liraglutide, Lennox et al. (2013) developed a novel GLP-1 peptide, (Val8)GLP-1-Glu-PAL, which contains a C16 fatty acid moiety (designated PAL) conjugated to Lys26 via a glutamic acid linker (Glu) in addition to an amino acid substitution at position 8.”
A brain-targeting lipidated peptide for neutralizing RNA-mediated toxicity in Polyglutamine Diseases
Zhang, Q. Y., Yang, M., Sørensen, K. K., Madsen, C. S., Boesen, J. T., An, Y., Peng, S. H., Wei, Y., Wang, Q., Jensen, K. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11695-y · Cited by 15
Kerr, B. D., Flatt, P. R., & Gault, V. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.021 · Cited by 15
Castillo, G. M., Reichstetter, S., & Bolotin, E. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0542-2 · Cited by 17
Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists
Jones, L. H., & Price, D. A. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00002-8 · Cited by 17
Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors
Lear, S., Amso, Z., & Shen, W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.008 · Cited by 15
Hegde, S. G., & Schmidt, M. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45028-9 · Cited by 15
Differentiating Incretin Therapies Based on Structure Activity, and Metabolism: Focus on Liraglutide
Grossman, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.25s · Cited by 16
“41 Alteration of the spacer region did not affect protraction of liraglutide, but it was found to optimize the potency of molecular interaction with GLP-1 receptor.(37) Liraglutide metabolism does not depend on one single organ responsible for its elimination.”
BackgroundAbubakar, M., Nama, L., Ansari, M. M., Ansari, M. M., Bhardwaj, S., Daksh, R., Syamala, K. L. V., Jamadade, M. S., Chhabra, V., Kumar, D., et al. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266293416240515075450 · Cited by 18
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
Merlino, D. J., Blomain, E. S., Aing, A., & Waldman, S. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030763 · Cited by 13
“Liraglutide (Victoza Novo Nordisk, Bagsværd, Denmark), shares 97% homology to native GLP-1 (7-37), but is conjugated to palmitic acid [73].”
Alexopoulou, F., Bech, E. M., Pedersen, S. L., Thorbek, D. D., Leurs, U., Rudkjær, L. C. B., Fosgerau, K., Hansen, H. H., Vrang, N., Jelsing, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05310-y · Cited by 14
Building a BioChemformatics Database
Jensen, J. H., Høeg-Jensen, T., & Padkjær, S. B. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800128b · Cited by 13
Demartis, A., Lahm, A., Tomei, L., Beghetto, E., Biasio, V. D., Orvieto, F., Frattolillo, F., Carrington, P. E., Mumick, S., Hawes, B. E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18494-5 · Cited by 13
Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders
Craig, S. L., Irwin, N., & Gault, V. A. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211043868 · Cited by 14
Huang, Y., Li, J., Chen, S., Zhao, S., Huang, J., Zhou, J., & Xu, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.922210 · Cited by 13
“Consequently, liraglutide not only maintains the efficacy of natural GLP-1, but also possesses strong chemical stability due to the presence of fatty acid side chains that resist degradation by DPP-IV and with the half-life of 12–14 h [6].”
BackgroundDiabetes and Cancer: Epidemiological, Clinical, and Experimental Perspectives
Tseng, C., Chen, C., & Landolph, J. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/101802 · Cited by 14
Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran, M., Willis, J. R., Dalvi, N., Fokakis, Z. N., VIRKUS, S., & Hardaway, J. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf019 · Cited by 12
Zhang, J., Dong, Y., Ju, D., & Feng, J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116291 · Cited by 12
A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease
Sessa, L., Concilio, S., Fominaya, J. M., Eletto, D., Piotto, S., & Busquets, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121315 · Cited by 12
Das, A., Geetha, K. M., & Hazarika, I. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09927-y · Cited by 12
Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation
Reed, A. B., Lanman, B. A., Holder, J. R., Yang, B. H., Ma, J., Humphreys, S. C., Wang, Z., Chan, J. C. Y., Miranda, L. P., Swaminath, G., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127499 · Cited by 12
Nissen, K. B., Andersen, J. J., Haugaard‐Kedström, L. M., Bach, A., & Strømgaard, K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501755d · Cited by 12
Tinsley, I. C., Borner, T., Swanson, M. L., Chepurny, O. G., Doebley, S. A., Kamat, V., Sweet, I. R., Holz, G. G., Hayes, M. R., Jonghe, B. C. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00185 · Cited by 11
Han, J. D. J., Meng, T., Chen, X., Han, Y., Fu, J., Zhou, F. L., Fei, Y., & Li, C. (2019) · The FASEB Journal · doi:10.1096/fj.201801479r · Cited by 11
“fective way to develop long-acting GLP-1 drugs (13, 14).”
BackgroundSmall-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives
Sun, X., Zhang, Z., Liu, M., Zhang, P., Nie, L., Liu, Y., Chen, Y., Xu, F., Liu, Z., & Zeng, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112722 · Cited by 10
Han, J. D. J., Fu, J., Sun, L., Han, Y., Mao, Q., Liao, F., Zheng, X., & Zhu, K. (2017) · MedChemComm · doi:10.1039/c7md00471k · Cited by 10
Reddiar, S. B., Abdallah, M., Styles, I. K., Müllertz, O. O., & Trevaskis, N. L. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114339 · Cited by 10
Incretin hormones and beta-cell mass expansion: what we know and what is missing?
Tortosa, F., & Dotta, F. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.795175 · Cited by 10
“These modifications lead to a slower absorption rate from the injection site, to a higher binding affinity to albumin and to a plasma half-life of 11 to 13 hours (Agersø et al., 2002; Madsen et al., 2007; Knudsen et al., 2000); consequently, liraglutide is administered subcutaneously once daily.”
BackgroundA first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol
Quinn, K., Traboni, C., Penchala, S. D., Bouliotis, G., Doyle, N., Libri, V., Khoo, S., Ashby, D., Weber, J. N., Nicosia, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09230-0 · Cited by 10
Classes of Drugs that Mitigate Radiation Syndromes
Micewicz, E. D., Damoiseaux, R. D., Deng, G., Gomez, A., Iwamoto, K. S., Jung, M. E., Nguyen, C., Norris, A. J., Ratikan, J. A., Ruchala, P. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.666776 · Cited by 10
Zhao, L., Wang, B., Wang, L., Xie, Z., Chen, Z., & Li-xia, S. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01132c · Cited by 10
Yang, S., Clemett, C. A., Brimble, M. A., O’Carroll, S. J., & Harris, P. W. R. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00172d · Cited by 9
Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
Cornell, S. A. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01302.x · Cited by 9
“Exogenous GLP-1 receptor agonists such as liraglutide show biological activity similar to native GLP-1 and are resistant to inactivation by DPP-4, because of prolonged absorption from subcutaneous tissue and from binding to albumin.(21,22) They are taken by subcutaneous injection, and treatment effects are targeted at…”
BackgroundEsposito, S., Krick, A., Pasquier, O., Bonche, F., Ingenito, R., Magotti, P., Bianchi, E., Monteagudo, E. S., Gallo, M. L., Cicero, D. O., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115256 · Cited by 10
Tian, H., Chang, M., Lyu, Y., Dong, N., Yu, N., Yin, T., Zhang, Y. X., He, H., Gou, J., & Tang, X. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2305110 · Cited by 9
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“This extended the half-life to 11–15 h through albumin binding that protects against cleavage by DPP4 and renal clearance, culminating in a reduction in HbA1c of 1.1–1.6 % and 5–10 % of body weight [34,35].”
InfluentialZhu, W., Tanday, N., Lafferty, R. A., Flatt, P. R., & Irwin, N. (2024) · BioFactors · doi:10.1002/biof.2059 · Cited by 8
Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity
Takeuchi, M., Okamoto, M., Okamoto, R., Kinoshita, H., Yamaguchi, Y., & Watanabe, N. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.014 · Cited by 8
King‐Ahmad, A., Kalgutkar, A. S. S., Niosi, M., Eng, H. F., & Holliman, C. L. (2018) · Bioanalysis · doi:10.4155/bio-2017-0239 · Cited by 8
Wolff, M., Schüler, A., Gast, K., Seckler, R., Evers, A., Pfeiffer‐Marek, S., Kurz, M. E., Nagel, N., Haack, T., Wagner, M., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01195 · Cited by 9
Zhou, J., Li, X., Zhu, X., Sun, J., Qiu, Q., Huang, W., & Qian, H. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12726 · Cited by 8
“They are many successful case; acylation (attachment of a fatty acid side chain) facilitated non-covalent binding to serum albumin in the GLP-1 analogue liraglutide (15).”
BackgroundMethodHan, J. D. J., Fu, J., Yang, Q., Zhou, F. L., Chen, X., Li, C., & Yin, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112389 · Cited by 8
Tordrup, E. K., Gadgaard, S., Windeløv, J. A., Holst, J. J., Gasbjerg, L. S., Hartmann, B., & ROSENKILDE, M. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116893 · Cited by 7
Huang, C., Wille, C. B., He, H., Reddy, V., Nargund, R. P., Lin, S., & Palani, A. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.02.031 · Cited by 7
Vana, V., Lærke, M. K., Kleberg, K., Mroz, P. A., Lindberg, B. L., Ekberg, J. H., Rehfeld, J. F., Schwartz, T. W., & Hansen, H. S. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113315 · Cited by 7
Graham, G. V., Conlon, J. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173101 · Cited by 7
“, 2020) and structureactivity studies involving human GLP-1 showed that the addition of a fatty acid and γglutamyl linker at certain sites in the molecule resulted in up to a 70-fold reduction in potency (Knudsen et al. 2000; Madsen et al. 2007).”
BackgroundGenetically Encoding a Lipidated Amino Acid for Extension of Protein Half‐Life in vivo
Fu, C., Chen, Q., Zheng, F. J., Yang, L., Li, H., Zhao, Q., Wang, X., Wang, L., & Wang, Q. (2018) · Angewandte Chemie · doi:10.1002/ange.201811837 · Cited by 7
Ni, S. J., Zhang, H., Huang, W. L., Zhou, J. P., & Qian, H. (2009) · Chinese Chemical Letters · doi:10.1016/j.cclet.2009.08.007 · Cited by 7
Lipopeptides as Therapeutics: Applications and In Vivo Quantitative Analysis
Zemenová, J., Sýkora, D., Maletínská, L., & Kuneš, J. (2016) · Bioanalysis · doi:10.4155/bio-2016-0206 · Cited by 7
Tang, C., Li, Q., Deng, X., Wu, W., Liao, L.-F., Liang, K., Huo, R., Li, C., Han, J. D. J., Tang, W., et al. (2020) · RSC Advances · doi:10.1039/d0ra01002b · Cited by 7
Chemical Insights into Oligonucleotide–Protein Binding for Therapeutic Applications
Gupta, S., Gupta, A., Mukherjee, M., Bose, S., & Sinha, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00427 · Cited by 6
Wang, C., Zhang, J., Dong, Y., Xu, J., Lu, J., Ding, C., Cai, Z., & Feng, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118266 · Cited by 6
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 6
Frimann, T. M., Ko, S. K., Harris, P., Bukrinski, J. T., & Peters, G. H. J. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2078409 · Cited by 6
“We believe that the bulkiness of the FA chains will prevent insertion into the receptor, and hence receptor activation, explaining why the potency is lower for this species (Madsen et al., 2007).”
BackgroundInfluentialHetero‐bivalent GLP‐1/Glibenclamide for Targeting Pancreatic β‐Cells
Hart, N. J., Chung, W. J., Weber, C. S., Ananthakrishnan, K., Anderson, M. J., Patek, R., Zhang, Z., Limesand, S. W., Vágner, J., & Lynch, R. M. (2013) · ChemBioChem · doi:10.1002/cbic.201300375 · Cited by 6
Kristensen, J. B., Elster, L., Lundh, M., Ballarín-González, B., Alexopoulou, F., Kræmer, M. K., Jensen, D. M., Leurs, U., Nielsen, J. C. F., Hansen, H. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84547-1 · Cited by 5
Yu, M., Zhang, C., Xu, H., Dong, Y., Zhu, H., Xia, C., & Feng, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-94014-0 · Cited by 5
“Specifically, we found that elongating fatty acid side chains and increasing OEG content significantly enhance albumin binding, consistent with prior reports 29,30 .”
A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
Jacobsen, M. T., Poulsen, C., Kopp, K. L., Olsen, J., & Cox, N. (2025) · Peptide Science · doi:10.1002/9781119824701.ch07 · Cited by 5
Su, Y., Zhang, S., Wu, Z., Liu, W.-T., Chen, J., Deng, F., Chen, F., Zhu, D., & Hou, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1054946 · Cited by 5
Probing the Binding Mechanism of Acylated Peptides to Human Serum Albumin
Hu, H., Ransdell, A. S., Qu, H., Durbin, J. D., Valenzuela, F. A., Hernandez-Buquer, S., & Gonciarz, M. D. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00018 · Cited by 5
Gómez‐Soler, M., Olson, E. J., de la Torre, E. R., Zhao, C., Lamberto, I., Flood, D. T., Danho, W., Lechtenberg, B. C., Riedl, S. J., Dawson, P. E., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115876 · Cited by 5
Lipid-conjugated Smac analogues
Micewicz, E. D., Ratikan, J. A., Waring, A. J., Whitelegge, J. P., McBride, W. H., & Ruchala, P. P. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.017 · Cited by 4
Preclinical Candidate Nomination and Development
Bergenhem, N. C. H. (2010) · Wiley eBooks · doi:10.1002/9780470915110.ch10 · Cited by 4
Metadata
- Authors
- Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-11-01
- Volume
- 50
- Issue
- 24
- Pages
- 6126-6132
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1978143294
- Cited by
- 244
- References
- 26
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 12 · 2023: 10 · 2022: 13 · 2021: 17 · 2020: 16 · 2019: 12 · 2018: 22 · 2017: 21 · 2016: 18 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 9
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- liraglutide, structure-activity relationship, protraction, spacer region, drug potency, GLP-1 receptor agonists, steric bulkiness
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cyclic AMP, Amino Acid Sequence, Animals, Cell Line, Fatty Acids, Cricetinae, Humans, Molecular Sequence Data, Structure-Activity Relationship, Swine, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.